TABLE 1.
Baseline characteristics included in a network meta-analysis of the treatment of locally advanced HNSCC patients.
| Study | Start-stop time | Tumor site | Sample size (No) | Median age | Control arm | Intervention arm | Reported outcome |
|---|---|---|---|---|---|---|---|
| Knowlton, A. H.1975 | - | HNSCC | 48/48 | 58 | RT | CCRT (Methotrexate + RT) | RR, OS, Toxicity |
| Percarpio, B.1976 | 1973.04-- | HNSCC | 17/18 | - | RT | Altered fractionation RT | OS, DFS |
| Shanta, V.1977 | 1971-- | OSCC | 62/74 | 49.4 | RT | CCRT (Bleomycin + RT) | RR, DFS |
| Fazekas, J. T.1980 | 1968–1972 | HNSCC | 326/312 | - | RT | IC Methotrexate + (RT) | OS |
| Petrovich, Z.1981 | 1975.07–1978.02 | HNSCC | 11/12 | 59 | RT | IC (Vincristine + Methotrexate) + RT | RR, OS |
| Weissberg, J. B. 1983 | 1973–1979 | HNSCC | 31/33 | 64 | RT | Altered fractionation RT | RR, Toxicity |
| Nissenbaum, M.1984 | 1979.12–1981.07 | HNSCC | 13/22 | 50 | RT | (Cisplatin + Bleomycin) | RR, OS |
| 13/23 | 52 | RT | CCRT (Cisplatin + Bleomycin + RT) | ||||
| Bogaert, W. 1986 | 1981.02–1984.10 | HNSCC | 164/161 | 58 | RT | Spilt Altered fractionation RT | LRC, OS |
| Fu, K. K.1987 | 1978.03–1984.08 | HNSCC | 51/45 | 57.2 | RT | CCRT (Bleomycin + RT) | RR, LRC, DFS, OS, Toxicity |
| Klima, A.1988 | - | HNSCC | 44/36 | 52 | (Cisplatin + Bleomycin + Methotrexate) | IC (Cisplatin + Bleomycin + Methotrexate) + RT | RR, OS |
| Sanchiz, F.1990 | 1978.01–1988.01 | HNSCC | 294/292 | 56 | RT | Altered fractionation RT | RR, PFS, OS, Toxicity |
| 294/306 | - | RT | CCRT (5-FU + RT) | ||||
| Pinto, L. H.1991 | 1986.04–1989.05 | OPSCC | 48/50 | 56 | RT | Altered fractionation RT | RR, OS, DFS |
| Tejedor, M.1992 | 1987.01–1989.07 | HNSCC | 17/19 | 57.4 | RT | IC (Carboplatin + Ftorafur) + RT | RR, OS, DFS, Toxicity |
| Weissler, M. C.1992 | - | HNSCC | 15/17 | 52 | Spilt Altered fractionation RT | Spilt CCRT (Cisplatin + 5-FU + RT) | RR, OS, PFS, DSS, Toxicity |
| Browman, G. P.1994 | 1987.04–1991.08 | HNSCC | 87/88 | 61 | RT | CCRT (5-FU + RT) | RR, OS, PFS, Toxicity |
| Kamioner, D.1994 | 1990.09–1992.09 | HNSCC | 17/20 | 55 | CCRT (Cisplatin + RT) | CCRT (Carboplatin + RT) | RR |
| Pinnarò, P.1994 | 1986.02–1991.02 | HNSCC | 49/44 | 57 | CCRT (Cisplatin + RT) | IC (Cisplatin + 5-FU) + RT | PFS, OS, LRC, RR, Toxicity |
| Smid, L.1995 | 1991.03–1993.10 | HNSCC | 25/24 | 50 | RT | CCRT (Mitomycin C + Bleomycin + RT) | RR, DFS, Toxicity |
| Antognoni, P.1996 | 1992.09–1993.09 | OPSCC, OSCC | 46/23 | 60 | RT | Altered fractionation RT | OS, LRC, Toxicity |
| Haddad, E.1996 | 1987.04–1992.10 | HNSCC | 28/28 | - | IC (Cisplatin + 5-FU) + RT | IC (Cisplatin + 5-FU) + CCRT (Cisplatin + 5-FU + RT) | RR |
| Merlano, M.1996 | 1987.02–1990.12 | HNSCC | 77/80 | - | RT | Alternate CCRT (Cisplatin + 5-FU + RT) | RR, LRC, PFS, OS, Toxicity |
| Horiot, J. C.1997 | 1985.12–1995.04 | HNSCC | 253/247 | 57 | RT | Altered fractionation RT | RR, LRC, OS, Toxicity |
| Jackson, S. M.1997 | 1991.10–1995.04 | HNSCC | 40/40 | 61 | RT | Altered fractionation RT | RFS, DSS, RR, Toxicity |
| Jeremic, B.1997 | 1988.01–1990.12 | HNSCC | 53/53 | 59 | RT | CCRT (Cisplatin + RT) | RR, OS, LRC, Toxicity |
| 53/53 | RT | CCRT (Carboplatin + RT) | |||||
| Benasso, M.1997 | 1983.08–1990.12 | HNSCC | 77/80 | - | RT | Alternate CCRT (Cisplatin + 5-FU + RT) | RR, OS |
| 55/61 | IC (Vinblastine + Bleomycin + Methotrexate) + RT | Alternate CCRT (Vinblastine + Bleomycin + Methotrexate + RT) | |||||
| Zakotnik, B. 1998 | 1991.03–1993.12 | HNSCC | 32/32 | 51 | RT | CCRT (Mitomycin C + Bleomycin + RT) | DFS, OS, RR, Toxicity |
| Wendt, T. G.1998 | 1989.11–1993.10 | HNSCC | 140/130 | 51 | Spilt Altered fractionation RT | Spilt CCRT (Cisplatin + 5-FU + RT) | OS, LRC, Toxicity |
| Calais, G.1999 | 1994.07–1997.09 | OPSCC | 113/109 | 56 | RT | CCRT (Carboplatin + 5-FU + RT) | OS, DFS, Toxicity |
| Santarelli, M.1999 | 1992–1997 | HNSCC | 66/61 | CCRT (Carboplatin + Etoposide + RT) | CCRT (5-FU + Mitomycin C + RT) | OS, Toxicity | |
| Dobrowsky, W. 2000 | 1990.10–1997.12 | HNSCC | 81/78 | 56 | RT | Altered fractionation RT | RR, OS, Toxicity |
| 81/80 | 56 | RT | CCRT (Mitomycin C + Altered fractionation RT) | ||||
| Jeremic, B. 2000 | 1991.01–1993.03 | HNSCC | 65/65 | 61 | Altered fractionation RT | CCRT (Cisplatin + Altered fractionation RT) | OS, PFS, LRC, Toxicity |
| Poulsen, M. G.2001 | 1991–1998 | HNSCC | 171/172 | 62 | RT | Altered fractionation RT | DFS, LRC, RR, DSS |
| Bartelink, H. 2002 | - | HNSCC | 24/25 | - | CCRT (Cisplatin + RT) | Spilt CCRT (cisplatin + Altered fractionation RT) | OS, LRC, Toxicity |
| Adelstein, D. J.2003 | 1992.03–1999.12 | HNSCC | 95/87 | 57 | RT | CCRT (Cisplatin + RT) | RR, OS, DSS, Toxicity |
| Grau, C.2003 | 1996.02–1999.12 | HNSCC | 221/245 | 55 | RT | CCRT (Mitomycin C + RT) | DSS, LRC, Toxicity |
| Denis, F.2004 | - | OPSCC | 112/108 | 55 | RT | CCRT (Carboplatin + 5-FU + RT) | OS, DFS, LRC, Toxicity |
| Garden, A. S.2004 | 1997.07–1999.06 | HNSCC | 78/77 | 56 | CCRT (Cisplatin + 5-FU + RT) | CCRT (Paclitaxel + Cisplain + RT) | RR, DFS, OS, Toxicity |
| Fountzilas, G.2004 | 1995.01–1999.07 | HNSCC | 41/45 | 57 | RT | CCRT (Cisplatin + RT) | PFS, OS, RR |
| 41/38 | 56 | RT | CCRT (Carboplatin + RT) | ||||
| Ezzat, M.2005 | 1998.05–2001.10 | HNSCC | 20/20 | 53.5 | RT | Altered fractionation RT | RR, OS, LRC, Toxicity |
| 20/20 | 51 | RT | CCRT (Mitomycin C + Altered fractionation RT) | ||||
| Bensadoun, R. J. 2006 | 1997.11–2002.03 | OPSCC, HPSCC | 82/81 | 54 | Altered fractionation RT | CCRT (Cisplain + 5-FU + Altered fractionation RT) | RR, OS, DFS, DSS, Toxicity |
| Bourhis, J. 2006 | 1994.11–1998.09 | HNSCC | 129/137 | RT | Altered fractionation RT | OS, LRC, Toxicity | |
| Fallai, C.2006 | 1993.01–1998.06 | OPSCC | 63/64 | 56.1 | RT | CCRT (Carboplatin + 5-FU + RT) | OS, DFS, Toxicity |
| Mitra, D.2006 | 1998.08–1999.07 | HNSCC | 90/90 | 56 | RT | IC (Cisplatin + 5-FU) + RT | RR, OS, Toxicity |
| Semrau, R. 2006 | 1995.07–1999.04 | HNSCC | 127/113 | 57 | Altered fractionation RT | CCRT (Carboplatin + 5-FU + Altered fractionation RT) | RR, LRC, OS, Toxicity |
| Turcato, G.2006 | - | HNSCC | 42/42 | - | CCRT (Cisplatin + 5-FU + RT) | IC (Docetaxel + Cisplatin + 5-FU) + CCRT (Cisplatin + 5-FU + RT) | RR, Toxicity |
| Manocha, S.2006 | 1998–2000 | HNSCC | 25/25 | 53 | RT | Alternate CCRT (Cisplatin + 5-FU + RT) | RR |
| Katori, H.2007 | 2000.01–2004.04 | HNSCC | 25/25 | 58 | CCRT (Docetaxel + Cisplatin + 5-FU + RT) | CCRT (Docetaxel + Cisplatin + 5-FU + Altered fractionation RT) | RR, DFS, LRC, OS, Toxicity |
| Chauhan, A.2008 | 2000.11–2003.03 | HNSCC | 40/40 | - | RT | CCRT (Gemcitabine + RT) | RR, Toxicity |
| Sarkar, S. K.2008 | 2005.01–2006.01 | HNSCC | 40/32 | - | CCRT (Cisplatin + RT) | CCRT (Vinorelbine + RT) | RR, Toxicity |
| Gupta, D.2009 | 2005.03–2007.07 | OPSCC | 57/48 | 50 | CCRT (Cisplatin + RT) | IC (Cisplatin + 5-FU) + CCRT (Cisplatin + RT) | RR, OS, DFS, Toxicity |
| Bonner, J. A.2010 | 1999.04–2002.03 | HNSCC | 213/211 | 57 | RT | Cetuximab + RT | OS, Toxicity |
| Devleena, D. M.2010 | 2004.09–2005.07 | HNSCC | 20/20 | 60 | CCRT (Cisplatin + RT) | CCRT (Vinorelbine + RT) | RR |
| Osorio R.M. 2010 | 2002.07–2007.02 | HNSCC | 51/54 | 63 | RT | CCRT (Nimotuzumab + RT) | OS, RR |
| Paccagnella, A. 2010 | 2003.01–2006.01 | HNSCC | 51/50 | 59 | CCRT (Cisplatin + 5-FU + RT) | IC (Docetaxel + Cisplatin + 5-FU) + CCRT (Cisplatin + 5-FU + RT) | RR, PFS, OS, Toxicity |
| Redda, M.G.R.2010 | 1992.11–1995.12 | HNSCC | 77/80 | 60 | RT | CCRT (Carboplatin + RT) | RR, DFS, OS, LRC, Toxicity |
| Campo, J. M. 2011 | 2006.03–2007.07 | HNSCC | 36/71 | 57 | CCRT (Cisplatin + RT) | IC Lapatinib + CCRT (Cisplatin + RT) | RR, Toxicity |
| Bourhis, J.2011 | 1996–2000 | HNSCC | 56/53 | 52 | Altered fractionation RT | Spilt CCRT (Cisplatin + 5-FU + Altered fractionation RT) | OS, Toxicity |
| Ghali, R. R.2011 | 2007.08–2009.09 | HNSCC | 30/30 | - | CCRT (Cisplatin + RT) | IC (Docetaxel + Cisplatin + 5-FU) + CCRT (Cisplatin + RT) | RR, Toxicity |
| Gregoire, V. 2011 | 2004.11–2008.06 | HNSCC | 116/110 | 53.2 | CCRT (Cisplatin + RT) | CCRT (Cisplatin + Gefitinib + RT) | OS, PFS, RR, LRC, Toxicity |
| Hamed, R. H.2011 | 2009.01–2010.06 | HNSCC | 26/25 | 58 | CCRT (Cisplatin + RT) | CCRT (Paclitaxel + RT) | RR, LRC, PFS, OS, Toxicity |
| Satapathy, B.2011 | 2007.09–2009.11 | HNSCC | 25/25 | 55 | CCRT (Cisplatin + RT) | IC (Cisplatin + 5-FU) + CCRT (Cisplatin + RT) | RR |
| Lorch, J. H. 2011 | 1999.05–2003.12 | HNSCC | 246/255 | 55 | IC (Cisplatin + 5-FU) + CCRT (Carboplatin + RT) | IC(Docetaxel + Cisplatin + 5-FU) + CCRT (Carboplatin + RT) | RR, OS, PFS, Toxicity |
| Kumar, S.2011 | 1995.08–1999.03 | HNSCC | 95/92 | 56 | RT | IC Cisplatin + (RT) | RR, Toxicity |
| 95/95 | RT | CCRT (Cisplatin + RT) | |||||
| Bourhis, J.2012 | 2000.02–2007.05 | HNSCC | 279/280 | 56.5 | CCRT (Carboplatin + 5-FU + RT) | CCRT (Carboplatin + 5-FU + Altered fractionation RT) | PFS, OS, LRC, Toxicity |
| 279/281 | 56.3 | CCRT (Carboplatin + 5-FU + RT) | Altered fractionation RT | ||||
| Halim, A. F.2012 | 2004.03–2006.12 | HNSCC | 110/106 | 51 | CCRT (Gemcitabin + RT) | CCRT (Paclitaxel + RT) | RR, PFS, OS, Toxicity |
| Choudhury, K.2012 | 2008.05–2012.05 | HNSCC | 46/42 | - | RT | Altered fractionation RT | RR, DFS, OS, Toxicity |
| Chitapanarux, I.2013 | 2003.01–2007.12 | HNSCC | 48/37 | 61 | CCRT (Carboplatin + 5-FU + RT) | Altered fractionation RT | OS, LRC, Toxicity |
| Gupta, S.2013 | 2004–2005 | HNSCC | 67/71 | 52 | IC (Paclitaxel + Cisplatin) + CCRT (Cisplatin + 5-FU + RT) | IC (Paclitaxel + Cisplatin) + CCRT (Cisplatin + Capecitabine + RT) | RR, DFS, PFS, OS, Toxicity |
| Haddad, R.2013 | 2004.08–2008.12 | HNSCC | 75/70 | 54 | CCRT (Cisplatin + RT) | IC (Docetaxel + Cisplatin + 5-FU) + CCRT (Docetaxel/Carboplatin + RT) | PFS, OS, Toxicity |
| Harrington, Kevin.2013 | 2006.11–2009.01 | HNSCC | 33/34 | 56 | CCRT (Cisplatin + RT) | CCRT (Cisplatin + Lapatinib + RT) | PFS, OS, LRC, RR, Toxicity |
| Martins, R. G.2013 | 2006.12–2011.10 | HNSCC | 105/99 | CCRT (Cisplatin + RT) | CCRT (Erlotinib + Cisplatin + RT) | RR, PFS, Toxicity | |
| Rishi, A.2013 | 2006.07–2010.06 | OPSCC | 106/110 | 51 | CCRT (Cisplatin + RT) | Altered fractionation RT | RR, DFS, Toxicity |
| Singh, P. K.2013 | 2008.12–2010.08 | OSCC | 30/30 | 55 | RT | CCRT (Geftinib + RT) | RR, DFS, Toxicity |
| Bhattacharya, B.2014 | 2011.01–2012.06 | HNSCC | 31/30 | - | CCRT (Cisplatin + RT) | CCRT (Gefitinib + Cisplatin + RT) | RR, Toxicity |
| Hitt, R.2014 | 2002.12–2007.05 | HNSCC | 128/155 | 57 | CCRT (Cisplatin + RT) | IC (Docetaxel + Cisplatin + 5-FU) + CCRT (Cisplatin + RT) | RR, PFS, OS, Toxicity |
| 128/156 | 57 | CCRT (Cisplatin + RT) | IC (Cisplatin + 5-FU) + CCRT (Cisplatin + RT) | ||||
| Reddy, B. K. 2014 | 2004.09–2005.07 | HNSCC | 20/20 | 51.8 | CCRT (Cisplatin + RT) | CCRT (Cisplatin + Nimotuzumab + RT) | RR, OS, Toxicity |
| 19/17 | 58.7 | RT | CCRT (Nimotuzumab + RT) | ||||
| Singh, M.2014 | - | OPSCC | 25/25 | - | CCRT (Cisplatin + RT) | CCRT (Cisplatin + 5-FU + RT) | RR, Toxicity |
| Ang, K. K.2014 | 2005.11–2009.03 | HNSCC | 447/444 | 57 | CCRT (Cisplatin + Altered fractionation RT) | CCRT (Cisplatin + Cetuximab + Altered fractionation RT) | OS, PFS, Toxicity |
| Nguyen. T. P. F. 2014 | 2002.02–2005.06 | HNSCC | 361/360 | 56 | CCRT (Cisplatin + RT) | CCRT (Cisplatin + Altered fractionation RT) | OS, PFS, Toxicity |
| Miszczyk, L.2014 | 2003.03–2009.09 | HNSCC | 37/39 | 57 | RT | Spilt Altered fractionation RT | RR, OS |
| Budach, V.2015 | 1995.03–1999.06 | HNSCC | 194/190 | 55 | Altered fractionation RT | CCRT (Mitomycin C + 5-FU + Altered fractionation RT) | OS, LRC, DSS |
| Chhatui, B. 2015 | 2008.09–2010.12 | OSCC | 25/25 | 50 | CCRT (Cisplatin + RT) | IC (Cisplatin + 5-FU) + CCRT (Cisplatin + RT) | RR, DFS, OS, Toxicity |
| Kumar, A. 2015 | 2012.03–2013.10 | HNSCC | 55/56 | 54 | Altered fractionation RT | CCRT (Cisplatin + Altered fractionation RT) | RR, PFS, OS, Toxicity |
| Lee, K. W. 2015 | - | HNSCC | 44/48 | - | IC (Docetaxel + Cisplatin) + CCRT (Cisplatin + RT) | IC (Docetaxel + Cetuximab + Cisplatin) + CCRT (Cetuximab + Cisplatin + RT) | RR, OS, PFS |
| Mesía, R.2015 | 2007.10–2009.03 | HNSCC | 63/87 | - | CCRT (Cisplatin + RT) | CCRT (Panitumumab + Cisplatin + RT) | RR, LRC, PFS, OS, Toxicity |
| Takacsi. N. Z.2015 | 2007.01–2009.06 | HNSCC | 33/33 | 56 | CCRT (Cisplatin + RT) | IC (Docetaxel + Cisplatin + 5-FU) + CCRT (Cisplatin + RT) | RR, OS, PFS, Toxicity |
| Rodriguez, C. P. 2015 | 2008.02–2011.10 | HNSCC | 35/34 | 57 | CCRT (Cisplatin + RT) | CCRT (Cisplatin + 5-FU + RT) | OS, RFS |
| Gupta, M.2015 | 2011.04–2013.05 | HNSCC | 67/66 | 57 | CCRT (Cisplatin + RT) | Altered fractionation RT | DFS, OS, RR, Toxicity |
| Giralt, J.2015 | 2007.11–2009.11 | HNSCC | 61/90 | - | CCRT (Cisplatin + Altered fractionation RT) | CCRT (Panitumumab + Cisplatin + Altered fractionation RT) | LRC, PFS, OS, Toxicity |
| Argiris, A.2016 | 2012.01–2014.09 | HNSCC | 37/41 | 56 | CCRT (Cetuximab + Pemetrexed + RT) | CCRT (Cetuximab + Pemetrexed + Bevacizumab + RT) | PFS, OS, Toxicity |
| Das, R.2016 | - | HNSCC | 29/28 | - | CCRT (Cisplatin + RT) | CCRT (Cisplatin + Altered fractionation RT) | RR, Toxicity |
| Driessen, C. M. L. 2016 | 2008.12–2012.02 | HNSCC | 27/29 | 53.4 | IC (Docetaxel + Cisplatin + 5-FU) + CCRT (Cisplatin + RT) | IC (Docetaxel + Cisplatin + 5-FU) + CCRT (Cisplatin + Altered fractionation RT) | PFS, OS, RR, LRC, Toxicity |
| Ghosh-Laskar, S.2016 | 2000.04–2007.10 | HNSCC | 57/65 | 56 | RT | CCRT (Cisplatin + RT) | LRC, DFS, OS, Toxicity |
| Hitt, R.2016 | - | HNSCC | 205/202 | 56 | IC (Docetaxel + Cisplatin + 5-FU) + CCRT (Cisplatin + RT) | IC (Docetaxel + Cisplatin + 5-FU) + (Cetuximab + RT) | RR, Toxicity |
| Magrini, S. M.2016 | 2011.01–2014.08 | HNSCC | 35/35 | 64 | CCRT (Cisplatin + RT) | (Cetuximab + RT) | LRC, OS, DSS, Toxicity |
| Mishra, H.2016 | 2012.02–2013.02 | HNSCC | 15/15 | 53 | CCRT (Paclitaxel + Cisplatin + RT) | Altered fractionation RT | RR, Toxicity |
| Seiwert, T. Y. 2016 | 2006.09–2010.04 | HNSCC | 57/53 | 57 | IC (Carboplatin + Paclitaxel + Cetuximab) + CCRT (Hydroxyurea + 5-FU + Cetuximab + Altered fractionation RT) | IC (Carboplatin + Paclitaxel + Cetuximab) + CCRT (Cisplatin + Cetuximab + Altered fractionation RT) | OS, PFS, Toxicity |
| Tao, Y.2016 | 2010.01–2012.01 | LSCC | 25/25 | 55 | IC (Pemetrexed + Cisplatin) + RT | IC (5-FU + Cisplatin) + RT | RR, OS, Toxicity |
| Ghi, M. G.2017 | 2008.03–2012.04 | HNSCC | 206/208 | 60.5 | CCRT (Cisplatin + 5-FU + RT)/(Cetuximab + RT) | IC (Cocetaxel + Cisplatin + 5-FU) + CCRT (Cisplatin + 5-FU + RT)/(Cetuximab + RT) | RR, OS, PFS, Toxicity |
| He, X.2017 | - | HNSCC | 56/52 | CCRT (Cisplatin + 5-FU + RT) | CCRT (Raltitrexed + Cisplatin + RT) | RR | |
| Specenier, P. M.2017 | 2008.04–2009.12 | HNSCC | 15/15 | 56.7 | IC (Docetaxel + Cisplatin + 5-FU + Cetuximab) + CCRT (Cetuximab + Cisplatin + RT) | IC (Docetaxel + Cisplatin + 5-FU + Cetuximab) + CCRT (Cetuximab + Carboplatin + RT) | RR, Toxicity |
| Zhe. T. M.2017 | 2013.06–2014.03 | HPSCC | 44/39 | 56 | RT | CCRT (Paclitaxel + RT) | RR, Toxicity |
| Geoffrois, L. 2018 | 2009.05–2013.08 | HNSCC | 179/151 | 56 | CCRT (Carboplatin + 5-FU + RT) | IC (Docetaxel + Cisplatin + 5-FU) + (Cetuximab + RT) | PFS, OS, LRC, Toxicity |
| Saini, S. K.2018 | - | HNSCC | 32/35 | 52 | CCRT (Cisplatin + RT) | CCRT (Cisplatin + Gefitinib + RT) | RR, OS, PFS, Toxicity |
| Sun, X. S.2018 | GORTEC 2015–01 | HNSCC | 66/67 | 65 | (Cetuximab + RT) | CCRT (Pembrolizumab + RT) | Toxicity |
| Tao, Y.2018 | 2008.01–2014.03 | HNSCC | 202/204 | 57 | (Cetuximab + RT) | CCRT (Carboplatin + 5-FU + cetuximab + RT) | OS, PFS, Toxicity |
| Al-Saleh, K.2019 | 2012.11–2017.11 | HNSCC | 22/18 | 51 | CCRT (Cisplatin + Altered fractionation RT) | CCRT (Cetuximab + Altered fractionation RT) | RR, DFS, OS, Toxicity |
| Gillison, M. L.2019 | 2011.06–2014.07 | OPSCC | 406/399 | 57.6 | CCRT (Cisplatin + Altered fractionation RT) | CCRT (Cetuximab + Altered fractionation RT) | OS, PFS, LRC, Toxicity |
| Keil, F.2019 | - | HNSCC | 49/51 | - | IC (Docetaxel + Cisplatin + 5-FU) + (Cetuximab + RT) | IC (Docetaxel + Cisplatin + Cetuximab) + (Cetuximab + RT) | RR |
| Patil, V. M. 2019 | 2012–2018 | HNSCC | 268/268 | 54.5 | CCRT (Cisplatin + RT) | CCRT (Cisplatin + Nimotuzumab + RT) | OS, PFS, DFS, LRC, Toxicity |
| Rastogi, M.2019 | 2006.03–2008.03 | HNSCC | 161/161 | 52 | CCRT (Cisplatin + RT) | Altered fractionation RT | LRC, DFS, OS, Toxicity |
| Yom, S. S.2019 | 2014.10–2017.02 | OPSCC | 157/149 | CCRT (Cisplatin + RT) | Altered fractionation RT | Toxicity | |
| Tao, Y.2020 | 2017.09–2018.08 | HNSCC | 21/21 | 61.4 | CCRT (Cisplatin + RT) | CCRT (Avelumabe + Cetuximabe + RT) | Toxicity |
| 20/20 | 61.4 | CCRT (Avelumabe + Cetuximabe + RT) | (Cetuximabe + RT) | ||||
| Fietkau, R.2020 | 2010–2015.02 | HNSCC | 111/105 | 59 | CCRT (Paclitaxel + Cisplatin + RT) | CCRT (Cisplatin + 5-FU + RT) | DFS, OS, Toxicity |
| Jones, D. A.2020 | 2012.11–2016.11 | OPSCC | 166/168 | 57.5 | CCRT (Cisplatin + RT) | (Cetuximab + RT) | OS |
| Lim, S. H.2020 | 2010.12–2015.04 | OPSCC, HPSCC | 19/17 | 61 | CCRT (Cisplatin + RT) | IC (Docetaxel + Cisplatin + 5-FU) + CCRT (Cisplatin + RT) | PFS, OS, RR, Toxicity |
| Maddalo, M.2020 | 2011.01–2014.08 | HNSCC | 35/35 | 64 | CCRT (Cisplatin + RT) | (Cetuximab + RT) | OS, LRC, DSS, Toxicity |
| Merlano, M. C. 2020 | 2009.09–2016.12 | HNSCC | 121/121 | 59.5 | CCRT (Cisplatin + RT) | IC (Docetaxel + Cisplatin + 5-FU) + (Cetuximab + RT) | OS, PFS, RR, Toxicity |
| Bourhis, J.2020 | 2016.05–2017.10 | HNSCC | 65/66 | 65 | (Cetuximab + RT) | CCRT (Pembrolizumab + RT) | PFS, OS, Toxicity |
| Cohen, E. E.2020 | 2016.12–2019.01 | HNSCC | 347/350 | - | CCRT (Cisplatin + RT) | CCRT (Avelumab + Cisplatin + RT) | PFS, Toxicity |
| Durga H. K. 2020 | - | HNSCC | 26/24 | - | CCRT (Cisplatin + RT) | CCRT (Paclitaxel + RT) | RR |
| Gupta, P.2020 | - | HNSCC | 30/30 | 58.1 | CCRT (Cisplatin + RT) | CCRT (Cisplatin + Altered fractionation RT) | RR, DFS, Toxicity |
| 30/30 | CCRT (Cisplatin + RT) | Altered fractionation RT | |||||
| Gebre-M. M.2021 | 2013.11–2018.03 | HNSCC | 145/146 | 61 | CCRT (Cisplatin + RT) | (Cetuximab + RT) | OS, Toxicity |